Siddharth Shah and family want to fix your smile. Pharmeasy 2.0 may need fixing first

Daybreak

The rise and fall of Pharmeasy is well documented. Once the poster child of the e-pharmacy boom, it reached a dizzying valuation of 5.6 bn USD at its very peak. But unfortunately, as we all know now, it didn’t last.

Today the company is worth just 450 million USD – which, is a 90 per cent drop. From aggressive acquisitions to regulatory hurdles, and a failed IPO, Pharmeasy’s journey has been a cautionary tale of overreach.

But the brains behind the operation – Siddharth Shah – isn’t done yet.

He’s back at it again with a new venture. Except this time, Shah has taken on the role of investor – while the founder spotlight is on his wife, Arpi Mehta. Their latest bet? MakeO – a startup that wants to bring invisible aligners, at-home cosmetic dentistry and dermatology treatments to your doorstep.

But despite its irresistible promise – convenience repackaged as medical-grade innovation – MakeO seems to be struggling to take off.

Turns out, MakeO is drawing quite heavily from the Pharmeasy playbook.

Will it end the same way?

Tune in.

Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.